Member Info for Ctw2014

Personally I thought this was a much better performance from Dan than in the useless Proactive interview following the RNS. Lots of time spent on the reasons for the increase in AISC. I still think there is lots to look forward to here and that my current paper loss will be quickly recovered and back into profit in the not to distant future. In my view the biggest error here has been poor communication and a failure to be up front on AISC and the reasons for it in the RNS and Proactive interview.

Disagree Ant. Ditch AIM and you lose buyers, me included!

The latest rise was largely fuelled by buyers on the American exchanges after the listings there in my opinion. The more the merrier in my view. It all increases demand for the same number of shares. Roll on the Czech listing, then the resource upgrade, and then the biggy for 2021, offtakes.

I just caught up with the video. Looked very solid to me and am not sure what more he could have said to please. With regard to Institutional investors, that was the point of the raise and we now have one. Nobody should forget that we also have CEZ with 51% at the project level. They might not be an institutional investor as such, but they are a huge company and are majority owned by the Czech government- surely a massive endorsement! I agree with Ant in that I regard this as my safest investment. It’s also one of the best performing shares I have held (albeit I have been in and out a bit to maximise profits) and I expect it to be one of my best performing shares going forward. Once off takes arrive (first half of 2021) we should see a re rate. All in my opinion only. Not advice of course. Please DYOR.

Anybody that missed this presentation who is interested in SYM should register with Investor meet Company and watch the presentation. It may be quiet here at the moment but there is a heck of a lot in the pipeline. Happy to wait patiently and notice that there is a steady trickle of buys and relatively few sells. Steady as she goes will do for now.

And calling your investment a pile of dung will help you get out?

So, at a guestimate of £20 per test to GDR (although I seem to recall Budd mentioning this figure - might be wrong) that's 5000 tests a 5 day working week (one shift only and they could work 7 days or more shifts) which equates to £5.2 million in potential revenues and that's per work station! Have I got that right??!! lol

So, at a guesstimate of £20 a test to GDR (although I seem to recall Budd mentioning this figure - might be wrong) that is 5000 tests a 5 day working week or £5million pa PER WORK STATION (potential). Happy to be corrected!

Either:

1) They have sold all they want to sell; or

2) They are drip feeding shares rather than dumping them to avoid crashing the price (which would not be in their interest)

Either way demand clearly exceeds supply

The AIHL test will sell itself. Practically guaranteed to be taken up wholesale across the NHS as it’s been trialled very successfully in two NHS hospitals. No hospital treating newborns will want to go without this test before treating a baby with the relevant antibiotic. No baby unit in the US will pass up on the test for fear of being sued for negligence. Will be a World wide product, starting with the more advance countries, such as UK, US, European, Japan, Canada etc. addressable world market estimated by GDR at £30 million (via distributors, more if sold direct) more than our market cap, and as we have no comparable competitor, we should be able to grab most of that and blow our market cap out of the water with just this one test. 30% under with my latest investment here (having sold earlier on the rise, but a bit too early to catch all of it) but totally comfortable that I will make money here again now we have more or less bottomed after the spike. Please do your own research and don’t be phased by noise. None of this is advice, just my opinion.

Another 1% gone. This is the real reason the SP is currently struggling, not perceived missed deadlines or anything else the company can control. Nobody knows how many they will sell but it is pretty clear that with their last conversion at about 22p they can be expected to take some profit. Even if they sell the lot it won’t take that long and we will be free to go back up. Having bounced of 42p a few times now it looks to me that they are being careful to manage the selling to keep the SP above that.

Well we know that proposals were being discussed just a few months ago so it would be surprising if he said anything else really. Everything has its price, but not at anything like this level imo.

Nice to see a bit of buying, presumably in anticipation of a positive trading update, especially on involvement with vaccine transportation etc.

It’s further recommendation and signals wider adoption. I am all for it.

All on track for first gas later this year is all I needed to hear. I too would expect a steady build in the SP this year barring any mishaps along the way. GLA and DYOR.

Cheers Caribbean- this is a get in at the bottom long term hold for me too. Not phased at all by daily fluctuations based on trivial volume.

Indeed - loads in the pipeline to come through.

Totally agree Ash. Last reported half year revenues were £8.2m up 5%. We have been told that Covid revenues are running at more than £500k in two months, so £3m extra per annum, and that’s without all the other positive developments that have only recently been reported. Just do your research, invest accordingly and ignore BB noise is my advice to anyone looking in.

Lovejoy22 - a very honest and sensible post. Well done.

Having looked around for a way to add to my exposure to gold stocks, and being a long term holder of HUM, I decided that I could do no better than take some CORA this morning at 9.4p. The big advantages are that it is incredibly cheap given that it has not risen in line with the gold price, it is well financed, the management have an excellent track record, the resource potential is great and there is an excellent prospect of this company transitioning from an explorer into a profitable producer, just like HUM has (with Bert Munro’s help). So Cora Is a great prospect in its own right as far as I am concerned, but an additional bonus is that it could easily become a take over target, wholly or partially, generally but also particularly given HUM’s proximity to Cora’s assets (especially the Yanfolila prospect) and HUM’s longer term ambitions. That could be good for both companies but either way, this looks like a winner and I am very pleased to be in at this price. I was pretty impressed with the terms of the June 2020 financing deal too. GLA